Telephone
1.833.462.8482
Address
Suite 220 28159 Avenue Stanford Valencia, CA 91355
Description
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 2.34 - 4.52
Trade Value (12mth)
AU$206,831.00
1 week
2.65%
1 month
17.87%
YTD
-25.66%
1 year
17.87%
All time high
104.14
EPS 3 yr Growth
130.50%
EBITDA Margin
-86.20%
Operating Cashflow
-$74m
Free Cash Flow Return
-69.70%
ROIC
-88.10%
Interest Coverage
-10.30
Quick Ratio
2.50
Shares on Issue (Fully Dilluted)
131m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.34
Date | Announcements |
---|---|
24 April 25 |
AVITA Medical to Host Acute Wound Care Showcase
×
AVITA Medical to Host Acute Wound Care Showcase |
23 April 25 |
Notice of Annual Meeting/Proxy Statement
×
Notice of Annual Meeting/Proxy Statement |
22 April 25 |
AVITA Medical to Announce First Quarter 2025 Results
×
AVITA Medical to Announce First Quarter 2025 Results |
10 April 25 |
AVH to Present Breakthrough Clinical Data at ABA 2025
×
AVH to Present Breakthrough Clinical Data at ABA 2025 |
07 April 25 |
Statement of CDIs on issue - AVH
×
Statement of CDIs on issue - AVH |
04 April 25 |
AVH Launches Cohealyx, Expanding U.S. Market Opportunity
×
AVH Launches Cohealyx, Expanding U.S. Market Opportunity |
03 April 25 |
Notification of cessation of securities - AVH
×
Notification of cessation of securities - AVH |
24 March 25 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
24 March 25 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
20 March 25 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
20 March 25 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
18 March 25 |
AVH Announces New Manufacturing AGMT & Amends Distribution
×
AVH Announces New Manufacturing AGMT & Amends Distribution |
11 March 25 |
Change of Director's Interest Notice - Robert McNamara
×
Change of Director's Interest Notice - Robert McNamara |
06 March 25 |
Statement of CDIs on issue - AVH
×
Statement of CDIs on issue - AVH |
05 March 25 |
Notification of cessation of securities - AVH
×
Notification of cessation of securities - AVH |
27 February 25 |
AVITA Medical to Present at TD Cowen Health Care Conference
×
AVITA Medical to Present at TD Cowen Health Care Conference |
27 February 25 |
Change of Director's Interest Notice - Robert McNamara
×
Change of Director's Interest Notice - Robert McNamara |
19 February 25 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
14 February 25 |
AVITA Medical Reports Q4 and FY2024 Financial Results
×
AVITA Medical Reports Q4 and FY2024 Financial Results |
14 February 25 |
AVITA Medical Q4 & FY 2024 Earnings Presentation
×
AVITA Medical Q4 & FY 2024 Earnings Presentation |
14 February 25 |
Financial Report Form 8-K dated 13 February 2025
×
Financial Report Form 8-K dated 13 February 2025 |
14 February 25 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
14 February 25 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
14 February 25 |
AVITA Medical to Host Investor Webinar Briefing
×
AVITA Medical to Host Investor Webinar Briefing |
06 February 25 |
Statement of CDIs on issue - AVH
×
Statement of CDIs on issue - AVH |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.